Z14.1 Insurance Policy Changes

ICD-10 Z14.1 is officially defined as "Cystic fibrosis carrier." code Z14.1 is referenced in 6 tracked payer policy changes from Excellus BlueCross BlueShield, Blue Cross Blue Shield of Rhode Island, and 2 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code Z14.1 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Excellus BlueCross BlueShield · Effective Jul 16, 2026High impact
Genetic Testing for Cystic Fibrosis 2.02.17
The July 16, 2026 update made expanded CFTR testing (CPT 81223) medically necessary when standard variant testing is insufficient to establish a diagnosis or assess reproductive risk, and when results will impact clinical or reproductive decision-making. Common-variant CF genetic testing is medically appropriate when results will impact clinical care, the test is performed by a CLIA-certified laboratory, and a listed circumstance applies, such as diagnostic testing for people with symptoms of CF and a negative sweat test, carrier testing for people with a family history of CF, or prenatal testing when both parents have a diagnosis of CF.
Blue Cross Blue Shield of Rhode Island · Effective Jul 1, 2025High impact
Medical policy updates
Effective July 1, 2025, clarifications for provider specialties were made to the outpatient professional behavioral health services policy for Medicare Advantage plans and commercial products. Effective September 1, 2025, transcranial magnetic stimulation (TMS) coverage changes from covered to covered only when filed with a covered ICD-10 code for the CPT codes in the TMS policy, for Medicare Advantage plans and commercial products. Effective September 1, 2025, prior authorization is removed for several genetic testing codes, and other codes move their medical criteria to the online authorization tool.
Blue Cross & Blue Shield of Mississippi · Effective Sep 1, 2025Medium impact
Cystic Fibrosis
Alyftrek (vanzacaftor, tezacaftor and deutivacaftor) is considered not medically necessary under this BCBSMS policy because there are other options covered by the Plan for cystic fibrosis. Kalydeco, Orkambi, Symdeko and Trikafta require prior authorization and are medically necessary for the listed age groups when the CFTR gene mutation is confirmed by genetic testing. The revision effective 09/01/2025 removed the CFTR gene mutation tables and revised the age, initial and renewal criteria, and the 05/26/2026 review left the policy statements unchanged.
Aetna · Identified Oct 4, 2026Medium impact
Genetic Testing (CPB 0140, reviewed 2026-08-18)
Aetna covers genetic testing only when the criteria for the specific condition are met, and it considers testing outside those criteria experimental, investigational, or unproven, including testing for Parkinson disease, essential tremor, coronary artery disease (except testing for familial hypercholesterolemia), and type 2 diabetes other than MODY. Multi-gene panels for inherited cancers are covered only for members with a personal or family history of a related cancer when more than one inherited cancer syndrome could explain the presentation and the panel is more efficient than separate tests, and genetic testing for inherited cancers is a once-in-a-lifetime benefit. Expanded carrier screening for people who are pregnant or planning a pregnancy is covered when the panel includes cystic fibrosis, spinal muscular atrophy, and/or hemoglobinopathies, unless previously performed, and the results will be used in managing the pregnancy or for family planning; whole exome or whole genome sequencing is covered for an unexplained congenital or neurodevelopmental disorder when its listed criteria are met, and whole genome sequencing after a non-diagnostic whole exome test is considered not medically necessary.
Aetna · Identified Aug 19, 2026Medium impact
Invasive Prenatal Diagnosis of Genetic Diseases (CPB 0358, reviewed 2026-05-22)
Aetna's Clinical Policy Bulletin 0358 considers invasive prenatal diagnosis by chorionic villus sampling (CVS), genetic amniocentesis, and percutaneous umbilical blood sampling (PUBS, cordocentesis) medically necessary for diagnosing fetal chromosomal abnormalities. Preimplantation genetic testing for monogenic disorders (PGT-M) is medically necessary only when the listed criteria are met, including a known carrier parent for the specific indication, a specific identified mutation, and a procedure that eliminates the need for later invasive prenatal diagnosis. PGT-A, PGT-M for fetal chromosomal abnormalities, PGT-M to determine HLA status for stem cell donation, multigene panels at PGT-M testing, and invasive screening or PGT for a variant of uncertain significance are considered experimental, investigational, or unproven, as are the Igenomix PGT-M, PGT-SR, Smart PGT-A and Smart PGT-A Plus tests, the IriSight Prenatal Analysis, and the Natera Spectrum PGT-M test.
Aetna · Identified Aug 17, 2026Medium impact
Genetic Counseling (CPB 0189, reviewed 2026-03-27)
Aetna considers genetic counseling medically necessary for listed pregnancy-related indications, including couples who are closely related genetically, familial cancer disorders, pregnant women with maternal age 35 years or greater at delivery, and parents of a child born with a genetic disorder or birth defect. Genetic counseling unrelated to pregnancy is covered when it is appropriate for, or provided with, medically necessary genetic testing in accordance with ACMG guidelines. Genetic counseling for all other indications is considered experimental, investigational or unproven.

Watch Z14.1

Get one email when a payer policy names Z14.1, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code Z14.1?

There are 6 tracked policy changes affecting code Z14.1, including updates from Excellus BlueCross BlueShield, Blue Cross Blue Shield of Rhode Island, Blue Cross & Blue Shield of Mississippi. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code Z14.1?

Payers that have issued tracked updates for code Z14.1 include: Excellus BlueCross BlueShield, Blue Cross Blue Shield of Rhode Island, Blue Cross & Blue Shield of Mississippi, Aetna.

How do I get notified when code Z14.1 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code Z14.1. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code Z14.1?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Genetic Testing for Cystic Fibrosis 2.02.17

Medical policy updates

Cystic Fibrosis

Genetic Testing (CPB 0140, reviewed 2026-08-18)

Invasive Prenatal Diagnosis of Genetic Diseases (CPB 0358, reviewed 2026-05-22)

Genetic Counseling (CPB 0189, reviewed 2026-03-27)

What insurance policy changes affect code Z14.1?

Which payers have updated policy for code Z14.1?

How do I get notified when code Z14.1 policy changes?

Why do payers change policies for code Z14.1?